CLINICAL STUDY OF CEFCLIDIN, A NEW INJECTABLE CEPHEM ON URINARY TRACT INFECTION

• Published in: CHEMOTHERAPY Vol. 40; no. Supplement4; pp. 411 - 416
• Main Authors: Suzuki, Keizo, Horiba, Masaki, Naide, Yorio, Hibi, Hideo, Okishio, Norihiko, Nagakubo, Ichiro, Ishiguro, Kooichi
• Format: Journal Article
• Language: English; Japanese
• Published: Japanese Society of Chemotherapy 1992
• Subjects: Cefclidin; UTI
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.40.Supplement4_411

Cefclidin (CFCL), a new derivative of injectable cephalosporins, was administered in the treatment of 39 patients with UTI, including 1 acute uncomplicated pyelonephritis (AUP) and 38 chronic complicated cystitis or pyelonephritis (CC-UTI). The results obtained were as follows. For one AUP caused by Escherichia coli, lg a day of CFCL was given for 3 days, and the efficacy was evaluated as excellent. CC-UTI patients were treated with several dosages such as 0.5g×2, 1g×1, 1g×2, a day for a 5 day course. The overall efficacy was evaluated as excellent in 5, moderate in 12, and poor in 7, with the rate of efficacy 71% by Japanese UTI criteria. In the bacteriological study, it was notable that 7 strains of Pseudomonas aeruginosa out of 9 were eradicated after the treatment. As for a safety profile, there were no side effects encountered. In laboratory tests there were transient and mild abnormal values which included an elevation of BUN, serum creatinine in one case, and that of S-GOT, S-GPT in another case, however they returned to normal after the discontinuance of the drug. CFCL was considered specially useful in the treatment of UTI caused by stubborn gram negative bacteria, including P. aeruginosa.